The EU-funded MycoSynVac project combines gene engineering and biotechnology to design a novel veterinary vaccine chassis based on the bacterium Mycoplasma pneumoniae.
– By combining their systems biology expertise with cutting-edge synthetic biology methodologies, researchers will engineer a universal chassis that is virulence-free and optimized for fast growth in a serum-free medium.
– This chassis will be used to create specific vaccines against two highly detrimental pathogens that attack livestock animals and cause large financial losses to the animal industry. The chassis also has other potential applications, such as for cell therapy and infectious lung disease treatment.
– MycoSynVac is a 8 M€ H2020 EU project coordinated by scientists at the Centre for Genomic Regulation in Barcelona (Spain) and with participation of industrial and academic partners in The Netherlands, France, UK, Germany, Denmark and Austria.
The Mycosplasma bacteria are the smallest self-replicating organisms. They lack a cell wall, making them resistant to almost all antibiotics, and infections caused by Mycoplasma in livestock result in annual multimillion euro losses in Europe and throughout the world. Although there are vaccines against two species of Mycoplasma that affect pigs and poultry, no vaccines exist for many Mycoplasma species that affect not only livestock but also pets and humans.
The new H2020 EU project MycoSynVac, starting in 2015, aims to bio-engineer Mycoplasma pneumoniae into a universal chassis for vaccination by using cutting-edge synthetic biology methodologies. “We will engineer a new bacteria to be used as a vaccine. We will first remove the genes that make the bacteria pathogenic and then improve the chassis for an optimized growth in a serum-free medium. By expressing specific harmless antigens from one or more pathogens, we can then create targeted vector vaccines”, explains Luis Serrano, director of the Centre for Genomic Regulation (CRG) and co-coordinator of this project. “We have been working for a long time to deeply understand Mycoplasma pneumoniae and are now ready to take a step forward and use this knowledge for the benefit of society”, adds Maria Lluch, staff scientist at the CRG and scientific co-coordinator of MycoSynVac. A second phase of this project includes targeting the development of attenuated (with the pathogen weaken but still alive) and/or inactivated vaccines (with killed pathogen) against M. hyopneumoniae, which infects pigs, and M. bovis, which infects cattle.
“This project pursues an ambitious challenge, and we recognize the importance of us taking into account not only its technical details but also its societal and ethical dimensions”, agree both coordinators. To effectively address these highly diverse aspects, the project consortium is composed of: research groups working on gene engineering and design of biological systems at the CRG (Barcelona, Spain), the French National Institute for Agricultural Research (Bordeaux, France), the Wageningen University (Wageningen, The Netherlands), and the Imperial College (London, UK); a research group focused on the bioethical aspects the University of Copenhagen (Copenhagen, Denmark); industrial partners of MSD Animal Health (Boxmeer, The Netherlands) and ATG Biosynthetics, a biotech company working on functional bioinformatics (Merzhausen, Germany); and the risk assessment and public engagement company Biofaction (Vienna, Austria).
Improving animal health & more
No effective vaccinations exist against many mycoplasmas that infect pets, humans and livestock. Research and development has been hampered by the fact that most mycoplasmas are difficult to grow without the presence of other organisms and require a complex media that includes animal serum. Consequently, even in those cases for which effective vaccines are available, the production process of the vaccines is hardly reproducible and prone to contamination by viruses.
To meet the needs of the livestock industry, MycoSynVac will capitalize on its scientists’ extensive systems biology knowledge about M. pneumoniae and on its cutting-edge synthetic biology methodologies to design a universal Mycoplasma chassis that can be deployed as single- or multi-vaccine in a range of animal hosts. Also, the engineered bacterium will grow efficiently and reproducibly in a defined serum-free medium, which will significantly improve its production, quality, and efficiency.
Researchers also foresee that the generated mycoplasma chassis can be further developed for other vaccines and will have other potential applications, such as in cell therapy and infectious lung disease therapy.
MycoSynVac is a 5-year project funded by the European Union’s Horizon 2020 Research and Innovation programme under grant agreement No 634942.
For further information and interviews:
Centre for Genomic Regulation – Press Office – Laia Cendrós
email: laia.cendros@crg.eu – Tel. +34 93 316 0237 – Mobile +34 607 611 798
This press release can also be found here.